Hepatitis
C Newsletter
www.HepCChallenge.org
May 2011
Clinical
Trials, Cohort Studies, Pilot Studies
Controlled release recombinant
human interferon-α2b for treating patients with chronic hepatitis C genotype 1:
a phase 2a clinical trial. Dzyublyk I, Yegorova T, Moroz L, et al. J
Viral Hepat. 2011 Apr;18(4):271-9.
doi:
10.1111/j.1365-2893.2010.01298.x.
http://www.ncbi.nlm.nih.gov/pubmed/20367790
Virological response is associated with
decline in hemoglobin concentration during pegylated
interferon and ribavirin therapy in hepatitis C virus
genotype 1. Sievert W, Dore GJ, McCaughan GW,
et al. Hepatology. 2011 Apr;53(4):1109-1117.
doi: 10.1002/hep.24180.
http://www.ncbi.nlm.nih.gov/pubmed/21480317
Excess mortality in patients with
advanced chronic hepatitis C treated with long-term peginterferon.
Di Bisceglie AM,
Stoddard AM, Dienstag JL, et al. Hepatology.
2011 Apr;53(4):1100-1108. doi: 10.1002/hep.24169.
http://www.ncbi.nlm.nih.gov/pubmed/21480316
Hepatitis C virus infection
causes hypolipidemia regardless of hepatic damage or
nutritional state: An epidemiological survey of a large Japanese cohort. Miyazaki
T, Honda A, Ikegami T, et al. Hepatol Res. 2011 Apr
19. doi:
10.1111/j.1872-034X.2011.00803.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21501354
A prospective study of the rate
of progression in compensated, histologically
advanced chronic hepatitis C (HEP-10-2210). Dienstag JL, Ghany MG, Morgan TR, et al. Hepatology.
2011 Apr 21. doi:
10.1002/hep.24370. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21520194
Association
of a single nucleotide polymorphism near the interleukin-28B gene with response
to hepatitis C therapy in Asian Patients. Sinn
DH, Kim YJ, Lee ST, et al. J Gastroenterol Hepatol. 2011 Apr 18. doi:
10.1111/j.1440-1746.2011.06744.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21501223
Basic
and Applied Science, Pre-Clinical Studies
A
common polymorphism in the ABCB11 gene is associated with advanced fibrosis in
hepatitis C but not in non-alcoholic fatty liver disease. Iwata R, Baur
K, Stieger B, et al. Clin Sci (Lond). 2011 Apr;120(7):285-6.
http://www.ncbi.nlm.nih.gov/pubmed/20883210
Regulation of Infectious Genotype 1a Hepatitis C
Virus Production by Domain III of NS5A. Kim S, Welsch
C, Yi M, Lemon SM. J Virol. 2011
Apr 27. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21525356
Temporal Variations in the Hepatitis C Virus
Intra-Host Population during Chronic Infection.
Ramachandran S, Campo DS, Dimitrova ZE, Xia GL, Purdy MA, Khudyakov
YE. J Virol. 2011
Apr 27. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21525348
Resistance
mutations define specific antiviral effects for inhibitors of the hepatitis C
virus (HCV) p7 ion channel. Foster
TL, Verow M, Wozniak AL, et al. Hepatology.
2011 Apr 21. doi:
10.1002/hep.24371. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21520195
Novel
Evolved Immunoglobulin (Ig)-Binding Molecules Enhance
the Detection of IgM against Hepatitis C Virus. Cao J, Chen Q,
Zhang H, et al. PLoS One. 2011 Apr 14;6(4):e18477.
http://www.ncbi.nlm.nih.gov/pubmed/21533225
Hepatitis
C Virus Protects Human B Lymphocytes from Fas-Mediated
Apoptosis via E2-CD81 Engagement. Chen Z, Zhu Y, Ren Y, et al. PLoS One. 2011 Apr 19;6(4):e18933.
http://www.ncbi.nlm.nih.gov/pubmed/21526201
Structural in silico
analysis of cross-genotype-reactivity among naturally occurring HCV
NS3-1073-variants in the context of HLA-A*02:01 allele.
Antunes DA, Rigo
MM, Silva JP, Cibulski SP, Sinigaglia
M, Chies JA, Vieira GF. Mol Immunol. 2011 Apr 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21513985
The
hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular
localization of the NS5A non-structural viral protein. Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, Elazar
http://www.ncbi.nlm.nih.gov/pubmed/21513964
Serum
chemokine levels are associated with the outcome of pegylated interferon and ribavirin
therapy in patients with chronic hepatitis C. Yoneda S, Umemura
T, Joshita S, et al. Hepatol
Res. 2011 Apr 19. doi:
10.1111/j.1872-034X.2011.00802.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21504519
HIV/HCV
Coinfection
The natural
history of liver cirrhosis in HIV-hepatitis C virus-coinfected
patients.
López-Diéguez M,
Montes ML, Pascual-Pareja JF, et al. AIDS. 2011 Apr 24;25(7):899-904.
http://www.ncbi.nlm.nih.gov/pubmed/21330908
Peginterferon alfa
and ribavirin for chronic hepatitis C in patients
eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a
systematic review and economic evaluation. Hartwell D, Jones J,
Baxter L, Shepherd J. Health Technol Assess. 2011 Apr;15(17):1-210.
http://www.ncbi.nlm.nih.gov/pubmed/21473834
Influence of antiretroviral
therapy on liver disease. Kovari H,
Weber R. Curr Opin HIV
AIDS. 2011 Apr 20. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21508839
Treatment of
acute hepatitis C infection in HIV-infected patients. Boesecke C, Rockstroh JK. Curr Opin HIV AIDS. 2011
Apr 23. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21519248
Very early
prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected
patients.
Araújo ES, Dahari H, Neumann AU, e al. J Viral Hepat. 2011
Apr;18(4):e52-60. doi: 10.1111/j.1365-2893.2010.01358.x.
http://www.ncbi.nlm.nih.gov/pubmed/20738775
Antiretroviral treatment
interruption leads to progression of liver fibrosis in HIV-hepatitis C virus
co-infection. Thorpe J, Saeed S, Moodie EE, Klein MB; for the Canadian Co-infection Cohort
Study (CTN222). AIDS. 2011 Apr 24;25(7):967-975.
http://www.ncbi.nlm.nih.gov/pubmed/21330904
IL28B gene polymorphisms and
viral kinetics in HIV/hepatitis C virus-coinfected
patients treated with pegylated interferon and ribavirin. Rallón NI, Soriano V, Naggie S, et al. AIDS. 2011 Apr 18. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21505315
Felt and Enacted Stigma Among HIV/HCV-Coinfected Adults:
The Impact of Stigma Layering. Lekas HM,
Siegel K, Leider J. Qual
Health Res. 2011 Apr 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21498828
Hepatitis B
and C infection and liver disease trends among human immunodeficiency
virus-infected individuals.
Buskin SE, Barash EA,
Scott JD, Aboulafia DM, Wood RW. World J Gastroenterol. 2011 Apr 14;17(14):1807-16.
http://www.ncbi.nlm.nih.gov/pubmed/21528052
Complementary
and Alternative Medicine
A single arm phase II study of a
Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic
hepatitis C patients. Deng G, Kurtz RC, Vickers A, Lau N, Yeung KS, Shia J, Cassileth B. J Ethnopharmacol. 2011 Apr 17. [Epub ahead of print]
Source
http://www.ncbi.nlm.nih.gov/pubmed/21527335
[Syndrome distribution among patients with
chronic hepatitis C and interventions of integrated traditional Chinese and
Western medicine: study protocol.] [Article in Chinese]
Nie HM, Gao
YQ, Chen JJ. Zhong Xi Yi Jie He Xue
Bao. 2011 Apr 15;9(4):365-373.
http://www.ncbi.nlm.nih.gov/pubmed/21486548
Epidemiology,
Diagnostics, and Miscellaneous Works
Racial differences in hepatitis C treatment
eligibility. Melia MT, Muir AJ, McCone J, et
al. Hepatology. 2011 Apr 12.
doi: 10.1002/hep.24358. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21488082
A
New Combination of Blood Test and Fibroscan for
Accurate Non-Invasive Diagnosis of Liver Fibrosis
Stages in Chronic Hepatitis C. Boursier J, de Ledinghen V, Zarski JP, et al.
http://www.ncbi.nlm.nih.gov/pubmed/21468012
Quality
of life in patients with various liver diseases: patients with HCV show greater
mental impairment, while patients with PBC have greater physical impairment. Tillmann HL, Wiese M, Braun Y, et al. J
Viral Hepat. 2011 Apr;18(4):252-61.
doi:
10.1111/j.1365-2893.2010.01292.x.
http://www.ncbi.nlm.nih.gov/pubmed/20337922
Barriers
to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection and
Sexually Transmitted Infections in Substance Abuse Treatment Programs in the
United States. Bini Deceased EJ, Kritz
S, Brown LS Jr, Robinson J, Alderson D, Rotrosen J. J
Addict Dis. 2011 Apr;30(2):98-109.
http://www.ncbi.nlm.nih.gov/pubmed/21491291
Risk
factors associated with Hepatitis C among female substance users enrolled in
community-based HIV prevention studies. Nurutdinova D, Abdallah
AB, Bradford S, O'Leary CC, Cottler LB. BMC Res
Notes. 2011 Apr 14;4(1):126. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21492467
A
comparison of four fibrosis indexes in chronic HCV: Development of new
fibrosis-cirrhosis index (FCI). Ahmad
W, Ijaz B, Javed FT, et al.
BMC Gastroenterol. 2011 Apr 21;11(1):44.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21507271
Potential role of safer injection facilities in
reducing HIV and Hepatitis C infections and overdose mortality in the United
States. Semaan S, Fleming P, Worrell C, Stolp H, Baack B, Miller M. Drug
Alcohol Depend. 2011 Apr 22. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21515001
Abbott
RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic
hepatitis C. Ikezaki H, Furusyo
N, Ihara T, et al. J Infect Chemother. 2011 Apr 29. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21528383
Liver
Cancer
A comparison of prognosis between patients with
hepatitis B and C virus-related hepatocellular
carcinoma undergoing resection surgery. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. World
J Surg. 2011 Apr;35(4):858-67.
http://www.ncbi.nlm.nih.gov/pubmed/21207029
Percutaneous Radiofrequency Ablation
for Pulmonary Metastases from Hepatocellular
Carcinoma: Results of a Multicenter Study in Japan. Hiraki T, Yamakado
K, Ikeda O, et al. J Vasc Interv
Radiol. 2011 Apr 29. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21531575
A
comprehensive analysis of the dynamic biological networks in HCV induced hepatocarcinogenesis. He B, Zhang H, Shi T. PLoS One.
2011 Apr 19;6(4):e18516.
http://www.ncbi.nlm.nih.gov/pubmed/21526182
The
toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral
loads and susceptibility to hepatocellular carcinoma
in chronic hepatitis C. Nischalke HD, Coenen M, Berger C, et
al. Int J Cancer. 2011 Apr 15.
doi: 10.1002/ijc.26143. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21500195
Altered
cytokine levels and increased CD4+CD57+ T cells in the peripheral blood of
hepatitis C virus-related hepatocellular carcinoma
patients. Shiraki T, Takayama
E, Magari H, et al. Oncol
Rep. 2011 Apr 12. doi:
10.3892/or.2011.1258. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21491089
Impact of radiation and hepatitis virus infection on
risk of hepatocellular carcinoma.
Ohishi W, Fujiwara S,
Cologne JB, et al. Hepatology. 2011 Apr;53(4):1237-45.
doi: 10.1002/hep.24207.